Alternatives to Paroxetine for Depression and Anxiety Disorders

First-Line Alternatives

The American Academy of Child and Adolescent Psychiatry recommends sertraline as a well-tolerated alternative with less risk of discontinuation syndrome compared to paroxetine 3, 4
The American Family Physician suggests escitalopram as a preferred option in elderly patients with fewer drug interactions 4
The American Academy of Child and Adolescent Psychiatry notes that citalopram may have fewer drug interactions via CYP450 enzymes compared to paroxetine 3
The Annals of Internal Medicine states that fluoxetine has a longer half-life, which may reduce discontinuation symptoms 1, 2
The Annals of Internal Medicine recommends venlafaxine as an effective alternative for both depression and anxiety disorders with possible advantages in treatment-resistant cases 5, 6
The Annals of Internal Medicine suggests duloxetine as a particularly useful option when depression is accompanied by pain symptoms 5

The Annals of Internal Medicine reports that head-to-head trials show no significant differences in efficacy between SSRIs for treating major depressive disorder 1, 2
The Annals of Internal Medicine notes that meta-analyses show statistically significant but clinically minimal differences between some agents 1
The Annals of Internal Medicine states that all second-generation antidepressants demonstrate similar improvements in quality of life measures 1
The Neuropsychopharmacology journal recommends escitalopram and sertraline as first-line options for social anxiety disorder 7
The Journal of the American Academy of Child and Adolescent Psychiatry notes that escitalopram, sertraline, and venlafaxine show similar efficacy for generalized anxiety disorder 3

The Journal of the American Academy of Child and Adolescent Psychiatry warns of a higher risk of discontinuation syndrome compared to other SSRIs 3
The American Family Physician notes that sertraline is generally well-tolerated with flexible dosing 4
The American Family Physician suggests that escitalopram may have fewer drug interactions and side effects 4
The Annals of Internal Medicine reports that bupropion is an alternative with lower sexual side effects but less effective for anxiety 1
The Annals of Internal Medicine notes that mirtazapine may have a faster onset of action (1-2 weeks vs 3-4 weeks) 5

The American Family Physician recommends citalopram, escitalopram, sertraline, and venlafaxine as preferred agents in elderly patients 4
The American Family Physician advises that paroxetine should generally be avoided in older adults due to anticholinergic effects 4
The Annals of Internal Medicine reports that the STAR*D trial showed similar remission rates (about 25%) when switching to sertraline, extended-release venlafaxine, or sustained-release bupropion after initial treatment failure 1, 6
The Annals of Internal Medicine notes that some smaller studies suggest venlafaxine may have advantages in treatment-resistant cases 6

The Journal of the American Academy of Child and Adolescent Psychiatry recommends a gradual taper when switching from paroxetine to another antidepressant to minimize discontinuation symptoms 3
The Annals of Internal Medicine suggests cross-tapering (gradually decreasing paroxetine while introducing the new medication) as a preferred method 2
The Annals of Internal Medicine advises monitoring for improvement in both depressive and anxiety symptoms within 4-6 weeks of adequate dosing 1
The Journal of the American Academy of Child and Adolescent Psychiatry warns to be alert for potential discontinuation symptoms when switching from paroxetine, including dizziness, sensory disturbances, anxiety, and irritability 3

The Journal of the American Academy of Child and Adolescent Psychiatry warns that abrupt discontinuation of paroxetine can lead to severe withdrawal symptoms - always taper gradually 3
The Journal of the American Academy of Child and Adolescent Psychiatry notes that assuming all SSRIs have identical side effect profiles can be misleading, as they differ in drug interactions and discontinuation risks 3
The Annals of Internal Medicine advises considering comorbid conditions when selecting alternatives, as some agents have advantages for specific symptom clusters 5
The Annals of Internal Medicine recommends allowing adequate trial duration, as full response may take 4-12 weeks 1